Lung Cancer Therapeutics Market Trend, Share, Growth, Size, Analysis and Forecast 2032

Lung Cancer Therapeutics Market Industry Prospective

The global Lung Cancer Therapeutics Market size was valued at USD 26.68 Billion in 2023 and is predicted to reach USD 56.05 Billion by the end of 2032. The market is expected to grow with a CAGR of 8.6% during the forecast period. The report analyzes the global Lung Cancer Therapeutics Market's growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Lung Cancer Therapeutics industry.

Request Free Sample

Lung Cancer Therapeutics Market: Overview

Cancer is a disease caused by an uncontrolled division of abnormal cells in part of the body. These extra cells slowly gather together to form a tissue mass called a tumor. It reduces the ability of lungs to supply oxygen to the bloodstream and lymphatic system. The leading cause of lung cancer is prolonged exposure to asbestos, cigarette, cigar, tobacco intake, pipe-smoking, exposer to pollution, and harmful radiations. The main symptoms of lung cancer are wheezing, coughing, chest pain, appetite loss, shortness of breath, and weight loss. Different therapies available for lung cancer include immunotherapy, vaccine therapy, radiation therapy, chemotherapy, and surgery.

Lung Cancer Therapeutics Market: Growth Dynamics

The lung cancer therapeutics market is predicted grow substantially, owing to the growing number of people suffering from lung cancer, rising number of smokers, increasing exposure to asbestos, escalating demand for targeted therapies, presence of innovative and efficient drugs, and accelerating unhealthy lifestyle patterns. Additionally, the introduction of nano medication for lung cancer treatment is also driving the lung cancer therapeutics market globally. However, the high cost of drugs, negative effects of radiation therapies and chemotherapies, and poor cancer diagnostic facilities may limit the lung cancer therapeutics market.

The report covers a forecast and an analysis of the lung cancer therapeutics market on a global and regional level. The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD Billion). The study includes the drivers and restraints of the lung cancer therapeutics market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the lung cancer therapeutics market on a global and regional level.

In order to give the users of this report a comprehensive view of the lung cancer therapeutics market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Request Free Sample

Lung Cancer Therapeutics Market Segmentation Analysis

The global lung cancer therapeutics market is fragmented based on cancer type, treatment, drug class, end-user, and distribution channel. Based on cancer type, the lung cancer therapeutics market includes small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). More than 85% of the lung cancers are found to be NSCLC. By treatment, the lung cancer therapeutics market includes immunotherapy, chemotherapy, targeted therapy, radiation therapy, and others. Based on drug class, the market is divided into multikinase inhibitors, EGFR inhibitors, alkylating agents, mitotic inhibitors, antimetabolites, and others. Antimetabolites are expected to show the highest CAGR in the future. Based on end-user, the lung cancer therapeutics market comprises hospitals, homecare, specialty clinics, and others. Based on distribution channel, the market for lung cancer therapeutics is categorized into retail pharmacy, hospital pharmacy, internet, and others.

Lung Cancer Therapeutics Market Regional Analysis

North America will dominate the lung cancer therapeutics market over the forecast timeframe, owing to the increasing occurrences of lung cancer and rising geriatric population demanding therapeutics. Additionally, changing lifestyles and growing prevalence of smoking is leading to an escalating number of lung cancer incidences in North America. Europe is predicted to be the second-largest lung cancer therapeutics market, owing to the favorable government funding in the field of research, analysis and development of innovative medication, and technological growth related to cancer. The majority of the revenue of the Asia Pacific lung cancer therapeutics market is generated by the emerging nations of India and China, due to the growth in the number of smokers suffering from lung cancer.

The report provides a company market share analysis to give a broader overview of the key players in the lung cancer therapeutics market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the lung cancer therapeutics market on a global and regional basis.

Lung Cancer Therapeutics Market: Report Scope

The global lung cancer therapeutics market is segmented based on cancer type, treatment, drug class, end-user, distribution channel, and region. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Some key players in the lung cancer therapeutics market are

• Hoffmann-La Roche
• Eli Lilly and Company
• Sanofi-Aventis
• Pfizer
• Celgene Corporation
• GlaxoSmithKline
• Boehringer Ingelheim
• Agennix
• AstraZeneca
• and Merck & Co.

This report segments the global Lung cancer therapeutics market into:

Global Lung Cancer Therapeutics Market: By Cancer Type

• Non-Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

Global Lung Cancer Therapeutics Market: By Treatment

• Immunotherapy
• Chemotherapy
• Targeted Therapy
• Radiation Therapy
• Others

Global Lung Cancer Therapeutics Market: By Drug Class

• Antimetabolites
• Alkylating Agents
• Mitotic Inhibitors
• EGFR Inhibitors
• Multikinase Inhibitors
• Others

Global Lung Cancer Therapeutics Market: By End-User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Lung Cancer Therapeutics Market: By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Internet
• Others

Global Lung Cancer Therapeutics Market: By Region

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa